About EOCI

EOCI has a demonstrated track record of over 13 years in the CME industry. Our reputation is a result of business integrity and professional agility, as well as resourcefulness and creativity.

In addition to the 25 to 30 CME programs we develop annually, EOCI produces other high-calibre specialist-focused annual congresses in Mont-Tremblant, and Montreal:

Arrhythmia Update Plus 2018

January 31 to February 3, 2018

Conference Educational Objectives

Following this program participants will be able to:

  • Discuss recent advances in the diagnosis and treatment of AF
  • Apply optimal management of left atrial appendage occlusion through devices and surgery
  • Understand the role of antithrombotic therapy in chronic vascular disease
  • Understand the role of anticoagulation in the prevention of cardiovascular events in patients with peripheral artery disease
  • Analyze recent evidence around the use of rivaroxaban for cardio-protection in chronic atherosclerosis
  • Discuss best practices following findings of long QT and Brugada patterns on ECG
  • Review evidence and expert opinion on the optimal management in AF
  • Analyze evidence around the cardioprotective effect of certain antihyperglycemics
  • Recognize the cardioprotective role of SGLT2 inhibitors and GLP-1 receptors
  • Examine the findings of BRUISE, RE-CIRCUIT, and PADIT
  • Analyze the evidence and expert opinion around the treatment of heart failure
  • Examine the findings of COMPASS and its implications on clinical practice
  • Define the optimal treatment for patients with AF and coronary disease
  • Recognize the role of the cardiologist in the management of diabetes
  • Apply optimal management in heart failure
  • Discuss best practices for the diagnosis and management of aortopathy
  • Examine and understand new concepts in management of heart failure
  • Improve ECG interpretation skills
  • Define the optimal medical and surgical management of aortopathy
  • Analyze the outcomes and the pharmacoeconomics around the use of PCSK9 inhibitors for the reduction of cardiovascular events
  • Identify recent advances in cardiac rhythm devices

Subscribe to get the latest updates

Receive the latest news on the Arrhythmia Update Conference directly in your mailbox.